Ronald Rapini, MD
Anatomic Pathology · Bellaire, TXNPI 1457307209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $297 of the $395 with a category attached, or 75.2%. 8 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 30.5% of the total. 2025 is the largest year on record at $247, 2.5 times the $98 reported in 2022.
Across 16 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$120
- Galderma Laboratories, L.p.$78
- Novartis$64
- Johnson & Johnson$58
- Amgen$29
- AbbVie$16
- plus $30 from 2 others
Across 3 payments — averaging $19,832 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin Pharmaceutical Development, Inc$59K
What the payments were for
- Food & beverage$29775%
- Education$9825%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 2 | $120 |
| Galderma Laboratories, L.p. | 2 | $78 |
| Novartis | 4 | $64 |
| Johnson & Johnson | 3 | $58 |
| Amgen | 2 | $29 |
| AbbVie | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Botanix SB Inc | 1 | $14 |
How this compares
$395 in reported general payments places this provider in the 70th percentile of 72 anatomic pathology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 26 | $97,349 |
| Metronidazole | 28 | $2,555 |
| Clobetasol Propionate | 63 | $2,363 |
| Triamcinolone Acetonide | 125 | $2,132 |
| Fluorouracil | 21 | $1,644 |
| Ketoconazole | 75 | $1,398 |
| Doxycycline Monohydrate | 22 | $895 |
| Fluocinonide | 17 | $824 |
| Doxycycline Hyclate | 20 | $622 |
| Clindamycin Phosphate | 16 | $593 |
| Hydrocortisone | 70 | $461 |
| Betamethasone Dipropionate | 12 | $393 |
| ValacyclovirValacyclovir Hcl | 22 | $372 |
| Mupirocin | 27 | $371 |
| Permethrin | 12 | $332 |
Paid to pharmacies, not to this prescriber.
Other anatomic pathology in Bellaire
- Donna HanselHouston$91K
- Robert GentaIrving$69K
- Alexander LazarHouston$64K
- Olga WeinbergDallas$62K
- Julian BryanHouston$20K
- Cesar MoranHouston$18K
- Francis GannonHouston$16K
- Peter McCaffreyGalveston$9K
- Richard HopleyDallas$6K
- Jeannelyn EstrellaHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.